Abstract | BACKGROUND: AIM: METHODS: Subjects were nonsmokers without history of asthma, with chronic cough for >8 weeks. All subjects underwent a baseline 24-h pH/impedance study, methacholine challenge test and laryngoscopy. Subjects were randomised to either 40 mg of esomeprazole twice daily or placebo for 12 weeks. The primary outcome measure was the Cough-Specific Quality of Life Questionnaire (CQLQ). Secondary outcomes were response on Fisman Cough Severity/Frequency scores and change in laryngeal findings. RESULTS: Forty subjects were randomised (22 PPI, 18 placebo) and completed the study. There was no difference between PPI and placebo in CQLQ (mean improvement 9.8 vs. 5.9 respectively, P = 0.3), or Fisman Cough Severity/Frequency scores. Proportion of patients who improved by >1 s.d. on the CQLQ was 27.8% (five of 18) and 31.8% (seven of 22) in the placebo and PPI groups respectively. CONCLUSION:
|
Authors | N J Shaheen, S D Crockett, S D Bright, R D Madanick, R Buckmire, M Couch, E S Dellon, J A Galanko, G Sharpless, D R Morgan, M B Spacek, P Heidt-Davis, D Henke |
Journal | Alimentary pharmacology & therapeutics
(Aliment Pharmacol Ther)
Vol. 33
Issue 2
Pg. 225-34
(Jan 2011)
ISSN: 1365-2036 [Electronic] England |
PMID | 21083673
(Publication Type: Journal Article, Randomized Controlled Trial, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
|
Copyright | © 2010 Blackwell Publishing Ltd. |
Chemical References |
- Proton Pump Inhibitors
- Esomeprazole
|
Topics |
- Adolescent
- Adult
- Aged
- Chronic Disease
- Cough
(complications, drug therapy)
- Double-Blind Method
- Esomeprazole
(therapeutic use)
- Female
- Gastroesophageal Reflux
(complications, drug therapy)
- Humans
- Male
- Middle Aged
- Proton Pump Inhibitors
(therapeutic use)
- Severity of Illness Index
- Statistics as Topic
- Treatment Outcome
- Young Adult
|